Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

632.10 +4.10 (+0.65%)
Streaming Delayed Price Updated: 9:47 AM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Gapping S&P500 stocks in Monday's session
Via Chartmill
Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today
Via Stocktwits
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
Regeneron Pharmaceuticals (NASDAQ:REGN) Presents a Compelling Case for Value Investors
Regeneron (REGN) presents a strong value investment case with a low P/E ratio, robust financial health, high profitability, and steady growth. 
Via Chartmill
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study
EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding. 
Via Benzinga
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Stocks Down 17% and 21% to Buy Right Now
Both companies have faced recent challenges, but look likely to overcome them. 
Via The Motley Fool
Topics World Trade
Why Are Regeneron And Scholar Rock Shares Falling On Monday?
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss
Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some participants. 
Via Benzinga
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Forecasting The Future: 9 Analyst Projections For Regeneron Pharmaceuticals
 
Via Benzinga
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients
FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, based on Phase 3 trial data. 
Via Benzinga
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness
A significant surge in capital flowing into short-bias Exchange-Traded Funds (ETFs) has sent a clear signal through the financial markets: investor sentiment is shifting towards caution and a potential... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent. 
Via Investor's Business Daily
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’
The FDA’s approval of Libtayo was based on Phase 3 trial data showing a 68% reduction in the risk of recurrence or death in high-risk CSCC patients. 
Via Stocktwits
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
Results of the Resolve-AD trial with rezpegaldesleukin were better than expected. 
Via The Motley Fool
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings
 
Via Benzinga
Wednesday's session: top gainers and losers in the S&P500 index
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday?
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat. 
Via Benzinga
Which S&P500 stocks are moving on Wednesday?
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Nvidia, Amphenol, Lockheed Martin And A Health Care Stock On CNBC's 'Final Trades'
Nvidia surges past 52-week high, surpasses $4.5 trillion market cap as tech companies invest in AI. Regeneron and Amphenol named as top trades. 
Via Benzinga
Topics Artificial Intelligence
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Topics Artificial Intelligence
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Beaten-Down Stocks to Buy and Hold for a Decade
These biotechs should benefit from their innovative ways. 
Via The Motley Fool
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
1 Healthcare Stock with Exciting Potential and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This... 
Via StockStory
Topics Stocks
FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder
The U.S. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.